NKG2A blockade potentiated NK cell-mediated ADCC against malignant B cells treated with CD40L and IL-4 and improved anti-CD20 antibody therapy in a murine model of B cell lymphoma. The gene discussed is KLRC1; the disease is B-cell non-Hodgkin lymphoma.